Inventor · disambiguated record
Gregory T. Stelzer
Also filed as: STELZER GREGORY T
10 granted patents·3 pending applications·590 citations·filing 1998–2016
92Inventor score
Top patents by PatentIndex Score
13 records- 0198US7674589B2Methods for tissue analysisGENENTECH INC·Filed 2008·Granted Mar 9, 2010·80 cites·24 claims
- 0298US6573043B1Tissue analysis and kits thereforGENENTECH INC·Filed 1998·Granted Jun 3, 2003·288 cites·15 claims
- 0397US7919254B2Tissue analysis and kits thereforGENENTECH INC·Filed 2010·Granted Apr 5, 2011·35 cites·7 claims
- 0497US7468252B2Methods for tissue analysisGENENTECH INC·Filed 2007·Granted Dec 23, 2008·51 cites·20 claims
- 0597US7344840B2Tissue analysis and kits thereforGENENTECH INC·Filed 2006·Granted Mar 18, 2008·43 cites·44 claims
- 0693US7129051B2Tissue analysis and kits thereforGENENTECH INC·Filed 2004·Granted Oct 31, 2006·36 cites·20 claims
- 0793US6905830B2Tissue analysis and kits thereforESOTERIX INC·Filed 2003·Granted Jun 14, 2005·51 cites·6 claims
- 0881US7943327B2Simultaneous assay of target and target-drug bindingLAB CORP AMERICA HOLDINGS·Filed 2007·Granted May 17, 2011·5 cites·12 claims
- 0967US8389224B2Assay for analysis of free drug in samplesPURVIS NORMAN B·Filed 2011·Granted Mar 5, 2013·1 cites·14 claims
- 1064US2014357522A1Simultaneous Assay of Target and Target-Drug BindingLAB CORP AMERICA HOLDINGS·Filed 2014·Application pending·0 cites
- 1162US2016161514A1Simultaneous Assay of Target and Target-Drug BindingLAB CORP AMERICA HOLDINGS·Filed 2016·Application pending·0 cites
- 1261US8828671B2Simultaneous assay of target and target-drug bindingLAB CORP AMERICA HOLDINGS·Filed 2013·Granted Sep 9, 2014·0 cites·14 claims
- 1345US2005266503A1Simultaneous assay of target and target-drug bindingESOTERIX INC·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Gregory T. Stelzer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →